18F-FDG PET/CT total lesion glycolysis is associated with circulating tumor cell counts in patients with stage I to IIIA non-small cell lung cancer

Diego M. Avella; Yariswamy Manjunath; Amolak Singh; Chelsea B. Deroche; Eric T. Kimchi; Kevin F. Staveley-O’Carroll; Jonathan B. Mitchem; Eric Kwon; Guangfu Li; Jussuf T. Kaifi

doi:10.21037/tlcr.2020.04.10

¹⁸F-FDG PET/CT total lesion glycolysis is associated with circulating tumor cell counts in patients with stage I to IIIA non-small cell lung cancer

Diego M. Avella, Yariswamy Manjunath, Amolak Singh, Chelsea B. Deroche, Eric T. Kimchi, Kevin F. Staveley-O’Carroll, Jonathan B. Mitchem, Eric Kwon, Guangfu Li, Jussuf T. Kaifi^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Abstract

Background: In non-small cell lung cancer (NSCLC), ¹⁸F-fluoro-2-deoxy-D-glucose (¹⁸F-FDG) uptake determined by PET and presence of circulating tumor cells (CTCs) in the peripheral blood independently predict outcomes. For ¹⁸F-FDG PET/CT staging interpretation, standardized uptake values (SUV_max/avg) are routinely used in clinical reporting. The goal was to investigate whether ¹⁸F-FDG uptake measured by SUV_max/avg, but also measures of metabolic tumor volume (MTV) and total lesion glycolysis (TLG) (MTV × SUV_avg), are associated with CTCs. Methods: Prospectively, 7.5 mL blood was drawn from NSCLC patients at the time of staging 18F-FDG PET/CT and from healthy control subjects. CTCs were identified by immunofluorescent staining (CK8/18/19^pos/EpCAM^pos/CD45^neg/DAPI^pos nucleus). ¹⁸F-FDG PET/CTs were analyzed for SUV_max, SUV_avg, MTV, and TLG. Results: In 16 NSCLC patients with stage I–IIIA, MTV and TLG, in contrast to SUV_max and SUV_avg, were positively associated with CTCs (linear regression analysis). No CTCs were detectable in 20 healthy control subjects. Conclusions: This pilot study demonstrates that ¹⁸F-FDG PET/CT TLG correlates with CTCs in NSCLC patients without distant metastases. TLG might be a more appropriate marker for hematogenous micrometastatic potential than SUVs.

Original language	English (US)
Pages (from-to)	515-521
Number of pages	7
Journal	Translational Lung Cancer Research
Volume	9
Issue number	3
DOIs	https://doi.org/10.21037/tlcr.2020.04.10
State	Published - Jun 1 2020
Externally published	Yes

Keywords

Circulating tumor cells (CTCs)
F-FDG PET/CT
Non-small cell lung cancer (NSCLC)
SUV
Total lesion glycolysis (TLG)

ASJC Scopus subject areas

Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.21037/tlcr.2020.04.10

Cite this

Avella, D. M., Manjunath, Y., Singh, A., Deroche, C. B., Kimchi, E. T., Staveley-O’Carroll, K. F., Mitchem, J. B., Kwon, E., Li, G., & Kaifi, J. T. (2020). ¹⁸F-FDG PET/CT total lesion glycolysis is associated with circulating tumor cell counts in patients with stage I to IIIA non-small cell lung cancer. Translational Lung Cancer Research, 9(3), 515-521. https://doi.org/10.21037/tlcr.2020.04.10

Avella, Diego M. ; Manjunath, Yariswamy ; Singh, Amolak ; Deroche, Chelsea B. ; Kimchi, Eric T. ; Staveley-O’Carroll, Kevin F. ; Mitchem, Jonathan B. ; Kwon, Eric ; Li, Guangfu ; Kaifi, Jussuf T. / ¹⁸F-FDG PET/CT total lesion glycolysis is associated with circulating tumor cell counts in patients with stage I to IIIA non-small cell lung cancer. In: Translational Lung Cancer Research. 2020 ; Vol. 9, No. 3. pp. 515-521.

@article{d5a71abcd92d4aa098d8cede0985f5d1,

title = "18F-FDG PET/CT total lesion glycolysis is associated with circulating tumor cell counts in patients with stage I to IIIA non-small cell lung cancer",

abstract = "Background: In non-small cell lung cancer (NSCLC), 18F-fluoro-2-deoxy-D-glucose (18F-FDG) uptake determined by PET and presence of circulating tumor cells (CTCs) in the peripheral blood independently predict outcomes. For 18F-FDG PET/CT staging interpretation, standardized uptake values (SUVmax/avg) are routinely used in clinical reporting. The goal was to investigate whether 18F-FDG uptake measured by SUVmax/avg, but also measures of metabolic tumor volume (MTV) and total lesion glycolysis (TLG) (MTV × SUVavg), are associated with CTCs. Methods: Prospectively, 7.5 mL blood was drawn from NSCLC patients at the time of staging 18F-FDG PET/CT and from healthy control subjects. CTCs were identified by immunofluorescent staining (CK8/18/19pos/EpCAMpos/CD45neg/DAPIpos nucleus). 18F-FDG PET/CTs were analyzed for SUVmax, SUVavg, MTV, and TLG. Results: In 16 NSCLC patients with stage I–IIIA, MTV and TLG, in contrast to SUVmax and SUVavg, were positively associated with CTCs (linear regression analysis). No CTCs were detectable in 20 healthy control subjects. Conclusions: This pilot study demonstrates that 18F-FDG PET/CT TLG correlates with CTCs in NSCLC patients without distant metastases. TLG might be a more appropriate marker for hematogenous micrometastatic potential than SUVs.",

keywords = "Circulating tumor cells (CTCs), F-FDG PET/CT, Non-small cell lung cancer (NSCLC), SUV, Total lesion glycolysis (TLG)",

author = "Avella, {Diego M.} and Yariswamy Manjunath and Amolak Singh and Deroche, {Chelsea B.} and Kimchi, {Eric T.} and Staveley-O{\textquoteright}Carroll, {Kevin F.} and Mitchem, {Jonathan B.} and Eric Kwon and Guangfu Li and Kaifi, {Jussuf T.}",

year = "2020",

month = jun,

day = "1",

doi = "10.21037/tlcr.2020.04.10",

language = "English (US)",

volume = "9",

pages = "515--521",

journal = "Translational Lung Cancer Research",

issn = "2226-4477",

publisher = "Society for Translational Medicine (STM)",

number = "3",

}

Avella, DM, Manjunath, Y, Singh, A, Deroche, CB, Kimchi, ET, Staveley-O’Carroll, KF, Mitchem, JB, Kwon, E, Li, G & Kaifi, JT 2020, '¹⁸F-FDG PET/CT total lesion glycolysis is associated with circulating tumor cell counts in patients with stage I to IIIA non-small cell lung cancer', Translational Lung Cancer Research, vol. 9, no. 3, pp. 515-521. https://doi.org/10.21037/tlcr.2020.04.10

¹⁸F-FDG PET/CT total lesion glycolysis is associated with circulating tumor cell counts in patients with stage I to IIIA non-small cell lung cancer. / Avella, Diego M.; Manjunath, Yariswamy; Singh, Amolak; Deroche, Chelsea B.; Kimchi, Eric T.; Staveley-O’Carroll, Kevin F.; Mitchem, Jonathan B.; Kwon, Eric; Li, Guangfu; Kaifi, Jussuf T.

In: Translational Lung Cancer Research, Vol. 9, No. 3, 01.06.2020, p. 515-521.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - 18F-FDG PET/CT total lesion glycolysis is associated with circulating tumor cell counts in patients with stage I to IIIA non-small cell lung cancer

AU - Avella, Diego M.

AU - Manjunath, Yariswamy

AU - Singh, Amolak

AU - Deroche, Chelsea B.

AU - Kimchi, Eric T.

AU - Staveley-O’Carroll, Kevin F.

AU - Mitchem, Jonathan B.

AU - Kwon, Eric

AU - Li, Guangfu

AU - Kaifi, Jussuf T.

PY - 2020/6/1

Y1 - 2020/6/1

N2 - Background: In non-small cell lung cancer (NSCLC), 18F-fluoro-2-deoxy-D-glucose (18F-FDG) uptake determined by PET and presence of circulating tumor cells (CTCs) in the peripheral blood independently predict outcomes. For 18F-FDG PET/CT staging interpretation, standardized uptake values (SUVmax/avg) are routinely used in clinical reporting. The goal was to investigate whether 18F-FDG uptake measured by SUVmax/avg, but also measures of metabolic tumor volume (MTV) and total lesion glycolysis (TLG) (MTV × SUVavg), are associated with CTCs. Methods: Prospectively, 7.5 mL blood was drawn from NSCLC patients at the time of staging 18F-FDG PET/CT and from healthy control subjects. CTCs were identified by immunofluorescent staining (CK8/18/19pos/EpCAMpos/CD45neg/DAPIpos nucleus). 18F-FDG PET/CTs were analyzed for SUVmax, SUVavg, MTV, and TLG. Results: In 16 NSCLC patients with stage I–IIIA, MTV and TLG, in contrast to SUVmax and SUVavg, were positively associated with CTCs (linear regression analysis). No CTCs were detectable in 20 healthy control subjects. Conclusions: This pilot study demonstrates that 18F-FDG PET/CT TLG correlates with CTCs in NSCLC patients without distant metastases. TLG might be a more appropriate marker for hematogenous micrometastatic potential than SUVs.

AB - Background: In non-small cell lung cancer (NSCLC), 18F-fluoro-2-deoxy-D-glucose (18F-FDG) uptake determined by PET and presence of circulating tumor cells (CTCs) in the peripheral blood independently predict outcomes. For 18F-FDG PET/CT staging interpretation, standardized uptake values (SUVmax/avg) are routinely used in clinical reporting. The goal was to investigate whether 18F-FDG uptake measured by SUVmax/avg, but also measures of metabolic tumor volume (MTV) and total lesion glycolysis (TLG) (MTV × SUVavg), are associated with CTCs. Methods: Prospectively, 7.5 mL blood was drawn from NSCLC patients at the time of staging 18F-FDG PET/CT and from healthy control subjects. CTCs were identified by immunofluorescent staining (CK8/18/19pos/EpCAMpos/CD45neg/DAPIpos nucleus). 18F-FDG PET/CTs were analyzed for SUVmax, SUVavg, MTV, and TLG. Results: In 16 NSCLC patients with stage I–IIIA, MTV and TLG, in contrast to SUVmax and SUVavg, were positively associated with CTCs (linear regression analysis). No CTCs were detectable in 20 healthy control subjects. Conclusions: This pilot study demonstrates that 18F-FDG PET/CT TLG correlates with CTCs in NSCLC patients without distant metastases. TLG might be a more appropriate marker for hematogenous micrometastatic potential than SUVs.

KW - Circulating tumor cells (CTCs)

KW - F-FDG PET/CT

KW - Non-small cell lung cancer (NSCLC)

KW - SUV

KW - Total lesion glycolysis (TLG)

UR - http://www.scopus.com/inward/record.url?scp=85090226434&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85090226434&partnerID=8YFLogxK

U2 - 10.21037/tlcr.2020.04.10

DO - 10.21037/tlcr.2020.04.10

M3 - Article

C2 - 32676315

AN - SCOPUS:85090226434

VL - 9

SP - 515

EP - 521

JO - Translational Lung Cancer Research

JF - Translational Lung Cancer Research

SN - 2226-4477

IS - 3

ER -